SAFETY DATA SHEET
Mometasone Dry Powder Inhaler Formulation

Version 2.8  Revision Date: 09/13/2019  SDS Number: 437332-00010  Date of last issue: 24.04.2019
Date of first issue: 28.01.2016

Section 1: Identification

Product name : Mometasone Dry Powder Inhaler Formulation

Manufacturer or supplier’s details
Company : MSD
Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand
Telephone : 908-740-4000
Emergency telephone number : 1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com
Telefax : 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

Section 2: Hazard identification

GHS Classification
Reproductive toxicity : Repr.1B
Specific target organ toxicity - repeated exposure (Inhalation) : STOT RE2 (Immune system, Liver, Kidney, Skin)

GHS label elements
Hazard pictograms :

Signal word : Danger
Hazard statements : H360Df May damage the unborn child. Suspected of damaging fertility.
H373 May cause damage to organs (Immune system, Liver, Kidney, Skin) through prolonged or repeated exposure if inhaled.

Precautionary statements : Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P281 Use personal protective equipment as required.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixture</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>&gt;= 10 - &lt; 30</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: May damage the unborn child. Suspected of damaging fertility. May cause damage to organs through prolonged or repeated exposure if inhaled. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment.
Section 5: Fire-fighting measures

Suitable extinguishing media
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media
- None known.

Specific hazards during firefighting
- Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products
- Carbon oxides
- Chlorine compounds

Specific extinguishing methods
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for firefighters
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

Hazchem Code
- 2Z

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures
- Use personal protective equipment.
- Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
Section 7: Handling and storage

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

Conditions for safe storage: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents.

Section 8: Exposure controls/personal protection

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wipe limit 10 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures: Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying...
from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

**Personal protective equipment**

**Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

- **Filter type**: Particulates type
- **Hand protection**
- **Material**: Chemical-resistant gloves

**Eye protection**

- **Remarks**: Consider double gloving.
- **Eye protection**
  - Wear safety glasses with side shields or goggles.
  - If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
  - Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**

- **Skin and body protection**
  - Work uniform or laboratory coat.
  - Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
  - Use appropriate degowning techniques to remove potentially contaminated clothing.

**Section 9: Physical and chemical properties**

- **Appearance**: powder
- **Colour**: white
- **Odour**: No data available
- **Odour Threshold**: No data available
- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flash point**: Not applicable
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: May form explosive dust-air mixture during processing, handling or other means.
SAFETY DATA SHEET

Mometasone Dry Powder Inhaler Formulation

Version 2.8  Revision Date: 09/13/2019  SDS Number: 437332-00010  Date of last issue: 24.04.2019
Date of first issue: 28.01.2016

Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapour pressure : No data available
Relative vapour density : No data available
Relative density : No data available
Density : No data available

Solubility(ies)
   Water solubility : No data available

Partition coefficient: n-octanol/water : No data available
Auto-ignition temperature : No data available
Decomposition temperature : No data available

Viscosity
   Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks. Avoid dust formation.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:
Mometasone:
Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

Skin corrosion/irritation
Not classified based on available information.

Components:
Mometasone:
Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Mometasone:
Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.
**Components:**

**Mometasone:**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Maximisation Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure routes</td>
<td>Dermal</td>
</tr>
<tr>
<td>Species</td>
<td>Guinea pig</td>
</tr>
<tr>
<td>Assessment</td>
<td>Does not cause skin sensitisation.</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Remarks</td>
<td>The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.</td>
</tr>
</tbody>
</table>

**Chronic toxicity**

**Germ cell mutagenicity**

Not classified based on available information.

**Components:**

**Mometasone:**

**Genotoxicity in vitro:**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Bacterial reverse mutation assay (AMES)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Test Type</td>
<td>Chromosomal aberration</td>
</tr>
<tr>
<td>Test system</td>
<td>Chinese hamster lung cells</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Test Type</td>
<td>Chromosomal aberration</td>
</tr>
<tr>
<td>Test system</td>
<td>Chinese hamster ovary cells</td>
</tr>
<tr>
<td>Result</td>
<td>positive</td>
</tr>
<tr>
<td>Test Type</td>
<td>Mouse Lymphoma</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

**Genotoxicity in vivo:**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Micronucleus test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Mouse</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Test Type</td>
<td>Chromosomal aberration</td>
</tr>
<tr>
<td>Species</td>
<td>Rat</td>
</tr>
<tr>
<td>Cell type</td>
<td>Bone marrow</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Test Type</td>
<td>unscheduled DNA synthesis assay</td>
</tr>
<tr>
<td>Species</td>
<td>Rat</td>
</tr>
<tr>
<td>Cell type</td>
<td>Liver cells</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

**Germ cell mutagenicity - Assessment:**

Weight of evidence does not support classification as a germ cell mutagen.

**Carcinogenicity**

Not classified based on available information.
Components:

Mometasone:

Species: Rat
Application Route: Inhalation
Exposure time: 2 Years
Dose: 0.067 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Inhalation
Exposure time: 19 Months
Dose: 0.160 mg/kg body weight
Result: negative

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:

Mometasone:

Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 0.015 mg/kg body weight
Symptoms: Reduced embryonic survival, Reduced foetal weight
Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal development: Test Type: Embryo-foetal development
Species: Mouse
Application Route: Subcutaneous
Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight
Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-foetal development
Species: Rat
Application Route: Dermal
Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight
Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Dermal
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development
Species: Rat
Application Route: Subcutaneous
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
Result: Effects on newborn

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight
Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

**STOT - single exposure**
Not classified based on available information.

**Components:**
*Mometasone:
Remarks: Based on available data, the classification criteria are not met.

**STOT - repeated exposure**
May cause damage to organs (Immune system, Liver, Kidney, Skin) through prolonged or repeated exposure if inhaled.

**Components:**
*Mometasone:
Exposure routes: inhalation (dust/mist/fume)
Target Organs: Immune system, Liver, Kidney, Skin
Assessment: May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**
*Mometasone:
Species: Rat
NOAEL: 0.005 mg/kg
LOAEL: 0.3 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Dog
LOAEL: 0.5 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Rat
NOAEL: 0.00013 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland
Species: Dog
NOAEL: 0.0005 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity
Not classified based on available information.

Components:
Mometasone: Not applicable

Experience with human exposure

Components:
Mometasone: Inhalation
Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact: Symptoms: Dermatitis, Itching

Further information

Components:
Mometasone: Remarks: Dermal absorption possible

Section 12: Ecological information

Ecotoxicity

Components:
Mometasone: Toxicity to fish
LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility
LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates
EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility
EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
**Toxicity to algae/aquatic plants**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>EC50 (Pseudokirchneriella subcapitata (green algae))</th>
<th>Exposure time</th>
<th>Method</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&gt; 3.2 mg/l</td>
<td>72 h</td>
<td>OECD Test Guideline 201</td>
<td>No toxicity at the limit of solubility</td>
</tr>
</tbody>
</table>

**Toxicity to fish (Chronic toxicity)**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>NOEC (Pimephales promelas (fathead minnow))</th>
<th>Exposure time</th>
<th>Method</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.00014 mg/l</td>
<td>32 d</td>
<td>OECD Test Guideline 210</td>
<td>No toxicity at the limit of solubility</td>
</tr>
</tbody>
</table>

**Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>NOEC (Daphnia magna (Water flea))</th>
<th>Exposure time</th>
<th>Method</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.34 mg/l</td>
<td>21 d</td>
<td>OECD Test Guideline 211</td>
<td>No toxicity at the limit of solubility</td>
</tr>
</tbody>
</table>

**Toxicity to microorganisms**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>EC50</th>
<th>Exposure time</th>
<th>Method</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&gt; 1,000 mg/l</td>
<td>3 h</td>
<td>OECD Test Guideline 209</td>
<td>No toxicity at the limit of solubility</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type</th>
<th>NOEC</th>
<th>Exposure time</th>
<th>Method</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1,000 mg/l</td>
<td>3 h</td>
<td>OECD Test Guideline 209</td>
<td>No toxicity at the limit of solubility</td>
</tr>
</tbody>
</table>

**Persistence and degradability**

**Components:**

**Mometasone:**

<table>
<thead>
<tr>
<th>Biodegradability</th>
<th>Result: Not readily biodegradable.</th>
<th>Biodegradation</th>
<th>Exposure time</th>
<th>Method</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>50 %</td>
<td>28 d</td>
<td>OECD Test Guideline 314</td>
<td>No toxicity at the limit of solubility</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stability in water</th>
<th>Hydrolysis: 50 % (12 d)</th>
<th>Method</th>
<th>OECD Test Guideline 111</th>
<th>No toxicity at the limit of solubility</th>
</tr>
</thead>
</table>

**Bioaccumulative potential**

**Components:**

**Mometasone:**

<table>
<thead>
<tr>
<th>Bioaccumulation</th>
<th>Species: Lepomis macrochirus (Bluegill sunfish)</th>
<th>Bioconcentration factor (BCF): 107.1</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bioconcentration factor (BCF): 107.1</td>
<td></td>
<td>No toxicity at the limit of solubility</td>
</tr>
</tbody>
</table>

| Partition coefficient: n-         | log Pow: 4.68                                  |                                      | No toxicity at the limit of solubility                                |
octanol/water

Mobility in soil

Components:

Mometasone:
Distribution among environmental compartments: $\text{log Koc} = 4.02$

Other adverse effects
No data available

Section 13: Disposal considerations

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class: 9
Packing group: III
Labels: 9

IATA-DGR
UN/ID No.: UN 3077
Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Mometasone)
Class: 9
Packing group: III
Labels: Miscellaneous
Packing instruction (cargo aircraft): 956
Packing instruction (passenger aircraft): 956
Environmentally hazardous: yes

IMDG-Code
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class: 9
Packing group: III
Labels: 9
EmS Code: F-A, S-F
Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
Not applicable for product as supplied.

**National Regulations**

**NZS 5433**
- UN number : UN 3077
- Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
- Class : 9
- Packing group : III
- Labels : 9
- Hazchem Code : 2Z

**Special precautions for user**
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## Section 15: Regulatory information

**Safety, health and environmental regulations/legislation specific for the substance or mixture**

**HSNO Approval Number**
HSR100425 Pharmaceutical Active Ingredients Group Standard 2017

**HSW Controls**
Certified handler certificate not required.
Tracking hazardous substance not required.
Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

**The components of this product are reported in the following inventories:**

<table>
<thead>
<tr>
<th>Inventory</th>
<th>Determination</th>
</tr>
</thead>
<tbody>
<tr>
<td>AICS</td>
<td>not determined</td>
</tr>
<tr>
<td>DSL</td>
<td>not determined</td>
</tr>
<tr>
<td>IECSC</td>
<td>not determined</td>
</tr>
</tbody>
</table>

## Section 16: Other information

**Further information**
Date format : dd.mm.yyyy
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NZ / EN